Identifying immune subtypes of uterine corpus endometrial carcinoma and a four-paired-lncRNA signature with immune-related lncRNAs

Exp Biol Med (Maywood). 2022 Feb;247(3):221-236. doi: 10.1177/15353702211053588. Epub 2021 Oct 27.

Abstract

Uterine corpus endometrial carcinoma (UCEC) is the third most frequent gynecological malignancies in the female reproductive system. Long non-coding RNAs (lncRNAs) are closely involved in tumor progression. This study aimed to develop an immune subtyping system and a prognostic model based on lncRNAs for UCEC. Paired lncRNAs and non-negative matrix factorization were applied to identify immune subtypes. Enrichment analysis was conducted to assess functional pathways, immune-related genes, and cells. Univariate and multivariate Cox regression analysis were performed to analyze the relation between lncRNAs and overall survival (OS). A prognostic model was constructed and optimized by least absolute shrinkage and selection operator (LASSO) and Akaike information criterion (AIC). Two immune subtypes (C1 and C2) and four paired-prognostic lncRNAs closely associated with overall survival were identified. Some immune features, sensitivity of chemotherapy and immunotherapy, and the relation with immune escape showed variations between two subtypes. A nomogram established based on prognostic model and clinical features was effective in OS prediction. The immune subtyping system based on lncRNAs and the four-paired-lncRNA signature was predictive of UCEC prognosis and can facilitate personalized therapies such as immunotherapy or RNA-based therapy for UCEC patients.

Keywords: Uterine corpus endometrial carcinoma; bioinformatics; immune subtypes; immune-related lncRNAs; lncRNAs; paired-lncRNAs.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Biomarkers, Tumor / genetics
  • Biomarkers, Tumor / immunology*
  • Endometrial Neoplasms / genetics*
  • Endometrial Neoplasms / immunology*
  • Endometrial Neoplasms / mortality
  • Endometrial Neoplasms / therapy
  • Female
  • Gene Expression Regulation, Neoplastic
  • Humans
  • Immunotherapy*
  • Mutation
  • Nomograms
  • Prognosis
  • RNA, Long Noncoding / genetics
  • RNA, Long Noncoding / immunology*
  • Treatment Outcome
  • Tumor Escape / genetics
  • Tumor Escape / immunology

Substances

  • Biomarkers, Tumor
  • RNA, Long Noncoding